Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio Partners with Vanda for Imsidolimab Development
- AnaptysBio, Vanda announce exclusive global license agreement for Vanda
- Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
- AnaptysBio price target lowered to $36 from $66 at JPMorgan
- AnaptysBio price target lowered to $20 from $30 at Truist